Physician
Family Medicine
Dr. Russell S. Thomas, MD
|
|
Give Review
Russell Thomas is an expert in the field of Family Medicine. He went to Emory University School of Medicine. Emory University School of Medicine is ranked 23 in research and 42 in primary care medicine Russell Thomas is a published doctor. He published 72 publications, including: 'Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor.' Russell Thomas is registered with Medicare.
Publications
- Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing.
- Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor.
- Predicting Hepatotoxicity Using ToxCast in Vitro Bioactivity and Chemical Structure.
- Aryl hydrocarbon receptor knock-out exacerbates choroidal neovascularization via multiple pathogenic pathways.
- Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing.
- Lineage dependent effects of aryl hydrocarbon receptor agonists contribute to liver tumorigenesis.
- In Vitro and Modelling Approaches to Risk Assessment from the U.S. Environmental Protection Agency ToxCast Programme.
- Development of 3D Dynamic Flow Model of Human Liver and its Application to Prediction of Metabolic Clearance of 7-Ethoxycoumarin.
- Subchronic toxicity evaluation of potassium bromate in Fischer 344 rats.
- Comparison of Microarrays and RNA-seq for Gene Expression Analyses of Dose-Response Experiments.
- Aryl hydrocarbon receptor deficiency causes dysregulated cellular matrix metabolism and age-related macular degeneration-like pathology.
- A Genomics-Based Analysis of Relative Potencies of Dioxin-Like Compounds in Primary Rat Hepatocytes.
- A Multi-Stakeholder Perspective on the Use of Alternative Test Strategies for Nanomaterial Safety Assessment.
- Subchronic Toxicity Evaluation of Anthraquinone in Fischer 344 Rats.
- Incorporating New Technologies into Toxicity Testing and Risk Assessment: Moving from 21st Century Vision to a Data-Driven Framework.
- Knockout of the aryl hydrocarbon receptor results in distinct hepatic and renal phenotypes in rats and mice.
- Subchronic hepatotoxicity evaluation of bromobenzene in Fischer 344 rats.
- Subchronic urinary bladder toxicity evaluation of N-Nitrosodiphenylamine in Fischer 344 rats.
- Temporal Concordance between Apical and Transcriptional Points-of-Departure for Chemical Risk Assessment.
- Evaluation of gene expression changes in human primary uroepithelial cells following 24-hr exposures to inorganic arsenic and its methylated metabolites.
- Reading between the lines: molecular characterization of five widely used canine lymphoid tumour cell lines.
- Cross-species transcriptomic analysis of mouse and rat lung exposed to chloroprene.
- The relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode-of-action from high-throughput in vitro toxicity assays.
- All-or-none suppression of B cell terminal differentiation by environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin.
- Integration of Dosimetry, Exposure and High-Throughput Screening Data in Chemical Toxicity Assessment.
- The aryl hydrocarbon receptor interacts with ATP5α1, a subunit of the ATP synthase complex, and modulates mitochondrial function.
- Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment.
- Regulation of Bach2 by the aryl hydrocarbon receptor as a mechanism for suppression of B-cell differentiation by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
- Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment.
- An integrated genomic analysis of aryl hydrocarbon receptor-mediated inhibition of B-cell differentiation.
- Formaldehyde: integrating dosimetry, cytotoxicity, and genomics to understand dose-dependent transitions for an endogenous compound.
- Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening.
- Genome-wide analysis of DNA methylation and gene expression changes in the mouse lung following subchronic arsenate exposure.
- Quantitative analyses and transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury.
- A bistable switch underlying B-cell differentiation and its disruption by the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin.
- Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation.
- Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4.
- Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators.
- The identification of protein kinase C iota as a regulator of the Mammalian heat shock response using functional genomic screens.
- Use of short-term transcriptional profiles to assess the long-term cancer-related safety of environmental and industrial chemicals.
- Dose-dependent transitions in Nrf2-mediated adaptive response and related stress responses to hypochlorous acid in mouse macrophages.
- In utero exposure to chloroquine alters sexual development in the male fetal rat.
- Genomic signatures and dose-dependent transitions in nasal epithelial responses to inhaled formaldehyde in the rat.
- Basal gene expression in male and female Sprague-Dawley rat nasal respiratory and olfactory epithelium.
- Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
- A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure.
- Application of genomic biomarkers to predict increased lung tumor incidence in 2-year rodent cancer bioassays.
- A comparison of transcriptomic and metabonomic technologies for identifying biomarkers predictive of two-year rodent cancer bioassays.
- EDGE: a centralized resource for the comparison, analysis, and distribution of toxicogenomic information.
- Dose-response modeling in reproductive toxicology in the systems biology era.
- Genome-scale functional profiling of the mammalian AP-1 signaling pathway.
- Stochastic simulation of hepatic preneoplastic foci development for four chlorobenzene congeners in a medium-term bioassay.
- Application of genomics to toxicology research.
- Developing toxicologically predictive gene sets using cDNA microarrays and Bayesian classification.
- A cellular genetics approach identifies gene-drug interactions and pinpoints drug toxicity pathway nodes.
- MYC Is an Early Response Regulator of Human Adipogenesis in Adipose Stem Cells.
- Biological responses in rats exposed to cigarette smoke and Middle East sand (dust).
- Chemical mixture toxicology: from descriptive to mechanistic, and going on to in silico toxicology.
- Expression profiling in canine osteosarcoma: identification of biomarkers and pathways associated with outcome.
- Systems pharmacology assessment of the 5-fluorouracil pathway.
- The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.
- BMDExpress: a software tool for the benchmark dose analyses of genomic data.
- NetAtlas: a Cytoscape plugin to examine signaling networks based on tissue gene expression.
- A functional map of NFkappaB signaling identifies novel modulators and multiple system controls.
- Genomic analysis of human lung fibroblasts exposed to vanadium pentoxide to identify candidate genes for occupational bronchitis.
- Stochastic modeling of B lymphocyte terminal differentiation and its suppression by dioxin.
- Genome-wide analysis of human HSF1 signaling reveals a transcriptional program linked to cellular adaptation and survival.
- Sequence variation and phylogenetic history of the mouse Ahr gene.
- A conditional density error model for the statistical analysis of microarray data.
- New directions in incidence-dose modeling.
- The Aryl-Hydrocarbon Receptor Protein Interaction Network (AHR-PIN) as Identified by Tandem Affinity Purification (TAP) and Mass Spectrometry.
Schools
Emory University School Of Medicine
Atlanta Med Center
Doctors Specialties
- Family Medicine
Accepted Insurances
- Assurant Health
- Blue Card PPO
- Blue Choice HMO
- Blue Choice Option POS
- Blue Open Access POS
- Direct Access w/HSA
- CHAMPVA
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- Emblem Health
- First Health (Coventry Health Care) PPO
- Group Health Cooperative
- Harvard Pilgrim Health Care PPO
- Choice Care PPO
- Mail Handlers Benefit Plan (MHBP)
- Medical Mutual of Ohio
- Medicare MCR
- Medico
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Planned Administration Inc
- POMCO Group
- Principal Life
- Priority Health
- Pyramid Life
- State Farm
- Tufts Health Plans
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- Wells Fargo Insurance
Education
-
Emory University School of Medicine
Hospital
-
Northside Hospital
Drug Facts
| NPI NUMBER | 1588693535 | |
| NPPES Provider LastName | THOMAS | |
| NPPES Provider FirstName | RUSSELL | |
| NPPES Provider ZIPCode | 300685425 | |
| NPPES Provider State | GA | |
| Specialty Description | Family Practice | |
| Total Claim Count | 3501.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 72.0 | |
| Percent Opioid Claims | 2.06 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1588693535 |
| Last Name Of The Provider | THOMAS |
| First Name Of The Provider | RUSSELL |
| View All |
Similar Doctors
|
|
Dr. William R. Almon, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bryan D. Blake, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Louis V. Cohen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Raymond F. Ramirez, MD |
|
|
Dr. Laurin G. Smith III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James M. Rogan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrea S. Videlefsky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brad L. Rohr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leonidas J. De Albuquerque, MD |
|
|
Dr. Rajiv M. Tejura, MD
This Doctor is OpenDoctor Recommended.
|